EMulate Therapeutics has developed a system for emulating the effects of solvated molecules via their magnetic field recordings. Recordings of magnetic field emissions of select small inhibitor RNAs (siRNAs; murine targeting CTLA-4 and murine targeting PD-1) were tested on C57Bl/6 mice implanted subcutaneously with the GL261 murine tumor cell line. A signal composed of concatenated recordings of siRNA molecules targeting the murine CTLA-4 and PD-1 receptors (labeled A2) was used in immune competent C57Bl/6 mice. The mice were flank implanted with the murine glioblastoma cell line GL261. Mice were exposed to the signal continuously (24 hours a day) until tumor volumes reached the designated volume limit. Tumors were excised and analyzed via PAGE/Western blot for the expression of CTLA-4, PD-1, Ki67, Caspase 3, CD4 and CD8. Terminal blood draws were used for CBCs. We report the down regulation of the checkpoint inhibitors CTLA-4 in the exposed mice. Significant tumor volume reduction was observed in mice exposed to the siRNA signal compared to control mice; no adverse events were recorded. Cell blood counts (CBC) and protein expression patterns were observed to correlate with the expected function of protein expression inhibition of the targets.
References
[1]
Thomas, Y., Schiff, M., Belkadi, L., Jurgens, P., Kahhak, L. and Benveniste, J. (2000) Activation of Human Neutrophils by Electronically Transmitted Phorbol-Myristate Acetate. Medical Hypotheses, 54, 33-39. https://doi.org/10.1054/mehy.1999.0891
[2]
Smith, J.A. and Weidemann, M.J. (1993) Further Characterization of the Neutrophil Oxidative Burst by Flow Cytometry. Journal of Immunological Methods, 162, 261-268. https://doi.org/10.1016/0022-1759(93)90391-j
[3]
Roy, D.K., Balanarayan, P. and Gadre, S.R. (2009) Signatures of Molecular Recognition from the Topography of Electrostatic Potential. Journal of Chemical Sciences, 121, 815-821. https://doi.org/10.1007/s12039-009-0097-5
[4]
Kloes, G., Bennett, T.J.D., Chapet-Batlle, A., Behjatian, A., Turberfield, A.J. and Krishnan, M. (2022) Far-field Electrostatic Signatures of Macromolecular 3D Conformation. Nano Letters, 22, 7834-7840. https://doi.org/10.1021/acs.nanolett.2c02485
[5]
Carvalho, C.S., Vlachakis, D., Tsiliki, G., Megalooikonomou, V. and Kossida, S. (2013) Protein Signatures Using Electrostatic Molecular Surfaces in Harmonic Space. PeerJ, 1, e185. https://doi.org/10.7717/peerj.185
[6]
Butters, J.T., Figueroa, X.A. and Butters, B.M. (2014) Non-Thermal Radio Frequency Stimulation of Tubulin Polymerization in Vitro: A Potential Therapy for Cancer Treatment. Open Journal of Biophysics, 4, 147-168. https://doi.org/10.4236/ojbiphy.2014.44015
[7]
Mukthavaram, R., Jiang, P., Pastorino, S., Nomura, N., Lin, F. and Kesari, S. (2024) Evaluation of the Emulate Therapeutics Voyager’s Ultra-Low Radiofrequency Energy in Murine Model of Glioblastoma. Bioelectronic Medicine, 10, Article No. 10. https://doi.org/10.1186/s42234-024-00143-8
[8]
Qiu, B., Sun, X., Zhang, D., Wang, Y., Tao, J. and Ou, S. (2012) TRAIL and Paclitaxel Synergize to Kill U87 Cells and U87-Derived Stem-Like Cells in Vitro. International Journal of Molecular Sciences, 13, 9142-9156. https://doi.org/10.3390/ijms13079142
[9]
Barkhoudarian, G., Badruddoja, M., Blondin, N., Chowdhary, S., Cobbs, C., Duic, J.P., et al. (2023) An Expanded Safety/feasibility Study of the Emulate Therapeutics Voyager™ System in Patients with Recurrent Glioblastoma. CNS Oncology, 12, CNS102. https://doi.org/10.2217/cns-2022-0016
[10]
Ulasov, I.V., Foster, H., Butters, M., Yoon, J., Ozawa, T., Nicolaides, T., et al. (2017) Precision Knockdown of EGFR Gene Expression Using Radio Frequency Electromagnetic Energy. Journal of Neuro-Oncology, 133, 257-264. https://doi.org/10.1007/s11060-017-2440-x
[11]
Rekulapelli, A., Flausino, L., Iyer, G. and Balkrishnan, R. (2022) Effectiveness of Immunological Agents in Non‐Small Cell Lung Cancer. Cancer Reports, 6, e1739. https://doi.org/10.1002/cnr2.1739
[12]
Reck, M., Ciuleanu, T., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., et al. (2023) First-line Nivolumab Plus Ipilimumab with Two Cycles of Chemotherapy versus Chemotherapy Alone (Four Cycles) in Metastatic Non-Small Cell Lung Cancer: Checkmate 9LA 2-Year Patient-Reported Outcomes. European Journal of Cancer, 183, 174-187. https://doi.org/10.1016/j.ejca.2023.01.015
[13]
Muto, I., Koga, H., Doi, R., Katayama, E., Nakama, K. and Nakama, T. (2022) Efficacy of Nivolumab and Ipilimumab Combined Therapy as a First-Line Therapy for Patients with Advanced Melanoma and the Urgent Need for an Effective Second-Line Therapy for Patients with Wild-Type BRAF in Japan: A Single Center Retrospective Study. The Kurume Medical Journal, 69, 75-80. https://doi.org/10.2739/kurumemedj.ms6912008
[14]
VanderWalde, A., Bellasea, S.L., Kendra, K.L., Khushalani, N.I., Campbell, K.M., Scumpia, P.O., et al. (2023) Ipilimumab with or without Nivolumab in PD-1 or PD-L1 Blockade Refractory Metastatic Melanoma: A Randomized Phase 2 Trial. Nature Medicine, 29, 2278-2285. https://doi.org/10.1038/s41591-023-02498-y
[15]
Li, H., Li, H., Tang, L., Niu, H., He, L. and Luo, Q. (2023) Associations between Immune-Related Venous Thromboembolism and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis, 29, 10760296231206799. https://doi.org/10.1177/10760296231206799
[16]
Zhu, Y., Liu, K., Zhu, H., Cao, H. and Zhou, Y. (2023) Comparative Efficacy and Safety of Novel Immuno-Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Network Meta-Analysis of Randomized Controlled Trial. Therapeutic Advances in Medical Oncology, 15, 17588359231206147. https://doi.org/10.1177/17588359231206147
[17]
Awan, S., Bharucha, P., Steventon, L., Simpson, H., AHMAD, T., Benafif, S., et al. (2023) Out-of-hours Admissions in Patients Treated with Immune Checkpoint Inhibitors and Their Primary Management with Steroids. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552231207271
[18]
Murphy, M., Dowling, A., Thien, C., Priest, E., Morgan Murray, D. and Kesari, S. (2019) A Feasibility Study of the Nativis Voyager® Device in Patients with Recurrent Glioblastoma in Australia. CNS Oncology, 8, CNS31. https://doi.org/10.2217/cns-2018-0017
[19]
Cobbs, C., McClay, E., Duic, J.P., Nabors, L.B., Morgan Murray, D. and Kesari, S. (2018) An Early Feasibility Study of the Nativis Voyager® Device in Patients with Recurrent Glioblastoma: First Cohort in US. CNS Oncology, 8, CNS30. https://doi.org/10.2217/cns-2018-0013
[20]
Camacho, L.H. (2015) CTLA‐4 Blockade with Ipilimumab: Biology, Safety, Efficacy, and Future Considerations. Cancer Medicine, 4, 661-672. https://doi.org/10.1002/cam4.371
[21]
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z. and Ma, D. (2023) Immune Checkpoint Therapy for Solid Tumours: Clinical Dilemmas and Future Trends. Signal Transduction and Targeted Therapy, 8, Article No. 320. https://doi.org/10.1038/s41392-023-01522-4
[22]
Wang, F., Xia, T., Li, Z., Gao, X. and Fang, X. (2023) Current Status of Clinical Trial Research and Application of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer. Frontiers in Oncology, 13, Article 1213297. https://doi.org/10.3389/fonc.2023.1213297
[23]
Kumar, P., Bhattacharya, P. and Prabhakar, B.S. (2018) A Comprehensive Review on the Role of Co-Signaling Receptors and Treg Homeostasis in Autoimmunity and Tumor Immunity. Journal of Autoimmunity, 95, 77-99. https://doi.org/10.1016/j.jaut.2018.08.007
[24]
Kim, M.J. and Ha, S. (2021) Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy. Frontiers in Cell and Developmental Biology, 9, Article 767466. https://doi.org/10.3389/fcell.2021.767466
[25]
Martens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M.A., Wong, P., Capone, M., et al. (2016) Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 22, 4848-4858. https://doi.org/10.1158/1078-0432.ccr-16-0249
[26]
Khoja, L., Atenafu, E.G., Templeton, A., Qye, Y., Chappell, M.A., Saibil, S., et al. (2016) The Full Blood Count as a Biomarker of Outcome and Toxicity in Ipilimumab‐treated Cutaneous Metastatic Melanoma. Cancer Medicine, 5, 2792-2799. https://doi.org/10.1002/cam4.878
[27]
Paterson, A.M., Lovitch, S.B., Sage, P.T., Juneja, V.R., Lee, Y., Trombley, J.D., et al. (2015) Deletion of CTLA-4 on Regulatory T Cells during Adulthood Leads to Resistance to Autoimmunity. Journal of Experimental Medicine, 212, 1603-1621. https://doi.org/10.1084/jem.20141030
[28]
Kumar, S., Singh, S.K., Rana, B. and Rana, A. (2021) Tumor-Infiltrating CD8+ T Cell Antitumor Efficacy and Exhaustion: Molecular Insights. Drug Discovery Today, 26, 951-967. https://doi.org/10.1016/j.drudis.2021.01.002
